Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P09.03 - Thyroid Dysfunction in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors (ICI): Outcomes in a Multiethnic Urban Cohort.
00:00 - 00:00 | Presenter: Angelica D'Aiello
- Abstract
Loading...
-
+
P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P14.03 - Histotype-dependent Associations of LAG-3 Expression with Clinicopathologic Features and Survival in Non-small Cell Lung Cancer
00:00 - 00:00 | Presenter: Dan Shepherd
- Abstract
Loading...
-
+
P21 - Locoregional and Oligometastatic Disease - Treatment of Locally Advanced NSCLC
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locoregional and Oligometastatic Disease
-
+
P21.10 - Real-World Treatment Patterns in Chinese Stage III NSCLC Patients - A Prospective, Non-Interventional Study (MOOREA trial)
00:00 - 00:00 | Presenter: Ligang Xing
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.36 - A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Juan Li
- Abstract
Loading... -
+
P76.47 - Molecular Characteristics and Response to Diverse EGFR TKIs of NSCLC Patients Harboring EGFR E709-T710delinsX
00:00 - 00:00 | Presenter: Wenfeng Fang
- Abstract
Loading...
